Lisinopril Can Cause Hypotension; Bactrim Does Not Directly Cause Hypotension But Increases Risk When Combined with ACE Inhibitors
Lisinopril (an ACE inhibitor) is well-documented to cause hypotension, particularly symptomatic hypotension in certain high-risk patients, while Bactrim (trimethoprim-sulfamethoxazole) does not directly cause hypotension but creates a dangerous drug interaction when combined with ACE inhibitors that can lead to hyperkalemia and potentially worsen hypotensive effects.
Lisinopril and Hypotension
Lisinopril causes hypotension through its mechanism of blocking angiotensin II formation, resulting in vasodilation. The FDA label explicitly warns that lisinopril "can cause symptomatic hypotension, sometimes complicated by oliguria, progressive azotemia, acute renal failure or death" 1.
High-Risk Patients for Lisinopril-Induced Hypotension:
- Heart failure patients with systolic BP below 100 mmHg
- Volume-depleted patients (especially those on diuretics)
- Patients with severe aortic stenosis or hypertrophic cardiomyopathy
- Elderly patients
- Patients with renal artery stenosis
- Those undergoing dialysis 1
The hypotension typically occurs within hours of the first dose or dose increases, and may be asymptomatic or present with dizziness, lightheadedness, or blurred vision 2, 3. Multiple heart failure guidelines emphasize that symptomatic hypotension should prompt evaluation but does not necessarily require discontinuation—instead, consider reducing diuretic doses or adjusting timing of medication administration 4, 5.
Bactrim and the Critical Drug Interaction
Bactrim does not cause hypotension as a direct pharmacologic effect. However, the 2019 AGS Beers Criteria specifically warns that "trimethoprim-sulfamethoxazole (TMP-SMX) should be used with caution by patients with reduced kidney function and taking an angiotensin-converting enzyme inhibitor (ACEI) or angiotensin receptor blocker (ARB) because of an increased risk of hyperkalemia" 6.
The Mechanism of Concern:
The 2012 ESC Heart Failure Guidelines explicitly list trimethoprim-sulfamethoxazole under "Drug interactions to look out for" when using ACE inhibitors, noting it can contribute to hyperkalemia 4. The 2018 European consensus document on hyperkalemia management also identifies TMP-SMX as a medication that decreases potassium excretion 7.
Severe hyperkalemia can lead to cardiac arrhythmias and hemodynamic instability, which could theoretically worsen or complicate existing hypotension from the ACE inhibitor, though this is an indirect rather than direct hypotensive effect.
Clinical Management Algorithm
When Starting or Adjusting Lisinopril:
- Check baseline blood pressure (supine and standing), renal function, and potassium 5, 1
- Start at low doses (2.5-5 mg daily) 5
- Monitor closely for 1-2 weeks after initiation or dose changes 5, 1
- If symptomatic hypotension occurs:
When Adding Bactrim to a Patient on Lisinopril:
- Check baseline potassium and renal function before starting Bactrim 6, 7
- Recheck potassium within 1 week of starting combination therapy 7
- Monitor for hyperkalemia symptoms: weakness, palpitations, arrhythmias
- If potassium rises above 5.0-5.5 mEq/L: Consider discontinuing one agent, reducing doses, or adding potassium-lowering therapy 4, 7
Common Pitfalls to Avoid
- Do not automatically discontinue lisinopril for asymptomatic hypotension—this is often expected and well-tolerated 4, 3
- Do not ignore the hyperkalemia risk when combining Bactrim with ACE inhibitors, especially in patients with renal impairment 6, 7
- Do not assume all hypotension in a patient on both medications is from lisinopril alone—consider volume depletion, sepsis (if Bactrim is treating infection), or other causes 1
- Do not overlook that Bactrim can cause rare but severe respiratory failure (TMP-SMX ARDS), which could present with hemodynamic instability, though this is unrelated to direct hypotensive effects 8